A major new meta-analysis from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has found that glucagon-like peptide 1 receptor agonists (GLP1-RAs)—a class of medications used to treat obesity and diabetes—may also offer benefits for emotional well-being in overweight users.
This article was originally published on MedicalXpress.com